Revance Therapeutics has extended the period of time in which Mylan must make a decision on whether it wants to continue the firms’ collaboration to develop and commercialize a biosimilar rival to Allergan’s Botox (onabotulinumtoxinA).
In the amended agreement filed by Revance with the US Securities and Exchange Commission, the firm gives Mylan until 30...